All news

24 October 2026

Biotech is having its best run since Covid, and dealmaking is a big reason why

A major biotech fund is up 24% this year after a 28% gain in 2025, helped by strong trial results and a jump in drug-company takeovers.

For a few years after Covid, biotech was the part of the stock market investors tried to forget. That has changed. The iShares Biotechnology ETF (IBB), a fund that holds 233 biotech stocks, was up 24% this year through October 23, on top of a 28% gain in 2025.

What happened

The gains are broad. Two dozen of the fund's holdings have more than doubled in 2026. The standout is Moderna, up 587% for the year even after an 18% drop on Thursday, when data from its cancer vaccine trial leaked early. The data were actually positive. Gene-sequencing company Illumina has also more than doubled.

Several forces are behind the move:

  • Trial results. Moderna and Merck's mRNA melanoma treatment cut the risk of cancer returning or death by 42% alongside Merck's Keytruda, and the companies aim to launch it in 2027. Eli Lilly's next-generation obesity drug, retatrutide, produced 28% to 30% weight loss at its highest doses.
  • Approvals. The FDA approved 46 new drugs in 2025, about a dozen of them novel biologics (drugs made from living cells), and roughly 66 more novel drugs are awaiting a decision.
  • Takeovers. Biopharma dealmaking hit $134 billion in the first half of 2026, already more than the $112 billion for all of 2025, according to BTIG analyst Jeet Mukherjee. Lilly alone has done 10 acquisitions worth $25 billion this year.

Why it matters

Big drugmakers face a patent cliff: products bringing in $180 billion of revenue will lose their patent protection by 2030, according to the RTW Institute. Once a patent expires, cheaper copies arrive and sales usually fall fast. That pushes large companies to buy smaller ones with promising drugs, and takeover bids tend to lift the whole sector.

The last biotech boom came during Covid, when near-zero interest rates made it cheap to fund early-stage drug developers. When rates rose, new listings and deals dried up and many young companies failed. Biotech is especially sensitive to rates because most firms spend years losing money before a drug reaches market.

The risks have not gone away. Moderna's rally, for instance, has come while the company is still losing money: Noorult data put its market value near $81 billion, against about $2.2 billion of revenue and a $3.2 billion net loss over the last twelve months of filings. Most drugs that enter trials never get approved.

What to watch

  • FDA decisions on the roughly 66 novel drugs in the queue.
  • Lilly's planned filing for retatrutide approval in the first quarter of 2027.
  • Whether the pace of drug-company takeovers holds up in the second half of the year.

Company pages for Moderna and Eli Lilly have their full financials.

The companies in this story

Based on reporting by CNBC: Biotech stocks rally on drug innovation and M&A. Facts, not advice.

More news